Skip to main content

PIK3CA-Related Overgrowth Spectrum clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

    open to eligible people ages 2 years and up

    This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).

    San Francisco, California and other locations

Our lead scientists for PIK3CA-Related Overgrowth Spectrum research studies include .

Last updated: